Dextromethorphan/bupropion vs Solriamfetol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: Dopamine/norepinephrine transporter · full Major Depressive Disorder pipeline
Dextromethorphan/bupropion · Auvelity
Marketed by Axsome Therapeutics
NCT02741791 · Phase 3 · completed
This was a randomized, double-blind, active-controlled trial with 312 participants, using change in the clinical MADRS depression score as its primary endpoint. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
Change in MADRS Total Score From Baseline to Week 6 (6 weeks): Change in MADRS Total Score From Baseline to Week 6 (6 weeks): AXS-05 15.91 score on a scale (Standard Error 0.921) vs Placebo 12.04 score on a scale (Standard Error 0.862) (met)
Result source: NCT04019704
Solriamfetol · Sunosi
Marketed by Axsome Therapeutics and partners
NCT06360419 · Phase 3 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2028 · NCT07484217 (registry estimate)
Reported efficacy
Montgomery-Åsberg Depression Rating Scale (MADRS) (6 weeks); Incidence of treatment-emergent adverse events (6 weeks): In the overall patient population the study did not demonstrate a statistically significant change on the Montgomery-Asberg Depression Rating Scale (MADRS) total score compared to placebo, the study's primary endpoint. Patients with MDD with severe excessive daytime sleepiness (n=51) and without severe EDS (n=295) were randomized to solriamfetol 300 mg or placebo. (missed)
Result source: NCT06360419
Results for Major Depressive Disorder
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Dextromethorphan/bupropion | Solriamfetol |
|---|---|---|
| MADRS, change (acute) | 15.9 vs 12.0+3.9 vs placeboNCT040197043 other results
| —Not posted · NCT06360419 |
| CGI-S, change (acute) | —Not posted · NCT02741791 | —Not posted · NCT06360419 |
| MADRS response | —Not posted · NCT02741791 | —Not posted · NCT06360419 |
| MADRS remission | —Not posted · NCT02741791 | —Not posted · NCT06360419 |
| Relapse (% of patients) | —Not posted · NCT02741791 | —Not posted · NCT06360419 |
MADRS, change (acute)
- Dextromethorphan/bupropion
- 15.9 vs 12.0+3.9 vs placeboNCT04019704
3 other results
- 13.7 vs 8.8 NCT03595579
- 17.2 vs 12.1 NCT03595579
- -11.6 vs -9.4 NCT02741791
- Solriamfetol
- —Not posted · NCT06360419
CGI-S, change (acute)
- Dextromethorphan/bupropion
- —Not posted · NCT02741791
- Solriamfetol
- —Not posted · NCT06360419
MADRS response
- Dextromethorphan/bupropion
- —Not posted · NCT02741791
- Solriamfetol
- —Not posted · NCT06360419
MADRS remission
- Dextromethorphan/bupropion
- —Not posted · NCT02741791
- Solriamfetol
- —Not posted · NCT06360419
Relapse (% of patients)
- Dextromethorphan/bupropion
- —Not posted · NCT02741791
- Solriamfetol
- —Not posted · NCT06360419
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Dextromethorphan/bupropion: 3 of 4 rows · Solriamfetol: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Dextromethorphan/bupropion |
|---|---|
| Dropout rate | 24.5%a NCT04019704 · Phase 3 show 2 more results20.8% NCT03595579 · Phase 2 93.9% NCT04039022 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT04019704 · Phase 3 show 2 more results— NCT03595579 · Phase 2 — NCT04039022 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 0.6%a NCT04019704 · Phase 3 show 2 more results0% NCT03595579 · Phase 2 2.4% NCT04039022 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | a all others, occurring in <5% of subjects 29% (placebo 26.2%) dizziness 16% (placebo 6.1%) nausea 13% (placebo 8.5%) NCT04019704 · Phase 3 show 2 more resultsdizziness 12.7% nausea 11.9% headache 8.8% NCT04039022 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Dextromethorphan/bupropion
show 3 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dextromethorphan/bupropion's landscape · Solriamfetol's landscape